(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 20.06% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Guardant Health's revenue in 2025 is $902,569,000.On average, 28 Wall Street analysts forecast GH's revenue for 2025 to be $124,770,594,823, with the lowest GH revenue forecast at $113,119,356,556, and the highest GH revenue forecast at $128,435,869,691. On average, 29 Wall Street analysts forecast GH's revenue for 2026 to be $156,921,155,805, with the lowest GH revenue forecast at $134,233,759,785, and the highest GH revenue forecast at $175,323,154,799.
In 2027, GH is forecast to generate $198,766,797,353 in revenue, with the lowest revenue forecast at $160,576,347,386 and the highest revenue forecast at $249,435,315,131.